Zydus Lifesciences Limited (Formerly known as ... They established a green field facility for Solid Oral Dosage Forms in Sikkim mainly for domestic market. They also installed Lyophilisation ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

The Padma Awards 2025 honour 139 individuals, including singer Arijit Singh, Bibek Debroy, Suzuki Motor’s ex-CEO Osamu Suzuki, among others for their contributions in various disciplines ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

How to Check Sikkim University Results 2025. Candidates can check their semester/annual results for various UG and PG courses online at the official website of the university. Follow the below ...

A female engineering student from Assam tragically died after allegedly jumping from her hostel building at a private college in Sikkim. Authorities are investigating whether it was a fall or suicide.

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral Sclerosis (ALS), a rare neurodegenerative disease. New Delhi, Jan 22 (PTI) Zydus ...

Zydus Lifesciences made headlines on Wednesday as the US health regulator bestowed Orphan Drug Designation upon Usnoflast, their developing treatment for amyotrophic lateral sclerosis (ALS). The US ...